Please login to the form below

Mark Mallon

This page shows the latest Mark Mallon news and features for those working in and with pharma, biotech and healthcare.

China approves Ironwood Pharma’s IBS treatment

The good news coincides with big changes at the US specialist pharma company, with a new CEO, AstraZeneca's Mark Mallon, and a splitting out into two separate companies. ... Mark Mallon, CEO, Ironwood Pharmaceuticals and Cyclerion. Ironwood and Allergan

Latest news

AZ’s Sean Bohen to exit after business overhaul; report

Chief commercial officer Mark Mallon has taken on the CEO role at US biotech Ironwood Pharmaceuticals, while Medimmune research head Bahija Jallal agreed to take the helm of UK biotech company
AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

The reshuffle coincides with the departure of two senior leaders: chief commercial officer Mark Mallon, who leaves to become chief executive of US biotech Ironwood Pharmaceuticals, and Bahija Jallal, who leaves
Grünenthal buys Zomig rights as AZ slimming drive continues

Mark Mallon, EVP, global product and portfolio strategy at AstraZeneca, said: “Grünenthal is an established partner with expertise in the treatment of pain.
AZ agrees to $320m deal for Zoladex

Mark Mallon, executive vice president of global product and portfolio strategy at AZ, said: “This agreement allows us to retain a significant share of the value of Zoladex in the US
AstraZeneca sets sights on China with Takeda deal

The company's executive vice president, international - Mark Mallon - said the increased investment "reinforces our commitment to bring innovative medicines from our exciting pipeline of targeted and biological medicines to patients

More from news
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest Intelligence

China: AstraZeneca’s new engine for growth and innovation

AstraZeneca’s Mark Mallon talks to PME about how its long-term investment in China is paying off. ... Mark Mallon is one of the chief architects of AstraZeneca’s current success in China.
Biopharma's Future: Made in China

Mark Mallon is executive vice president of Global Product &Portfolio Strategy at AstraZeneca, and before that spent many years as the company’s head of China and then the wider Asia ... AZ's Mark Mallon. “We have built the right culture there,”

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Senior Account Manager: Competitive

Healthcare Lead Copywriter: Competitive

Healthcare Account Director: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Account Director – Creative Healthcare Communications: Competative

Medical Editor: Competitive

PMHub

Add my company

Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

The search for effective drug treatments for COVID-19: PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....